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Abstract Abundant expression of somatostatin receptors
(SSTR) is frequently identified in differentiated neuroen-
docrine tumors and may serve as potential target for
diagnostic imaging and treatment. This article discusses the
‘‘theranostic approach’’ of SSTR-targeting compounds
including an overview of its role for diagnosis, staging and
restaging, discussing its way to being established in clinical
routine, and giving an outlook about further potentially
relevant developments.
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Introduction
Recent developments in cancer research have resulted in a
wide spectrum of therapies. Due to the large heterogeneity
of patients and tumors, there is an increasing demand for
personalized medicine. Introduction of the theranostic
approach is based on the idea of selecting patients through
a diagnostic study indicating whether a patient will benefit
from a therapy or not.
The theranostic principle has been applied in the field
of nuclear medicine for more than 60 years and 131I and
89Sr are still established in daily clinical routine. 131I
was first discovered in 1938 by Seaborg and Livingood
at the University of California Berkeley. Already in
1946, Seidlin et al. [1] reported the therapeutic use of
131I for patients with metastasized adenocarcinoma of
the thyroid. Since then the combination of radiolabeled
iodine for diagnostic imaging and therapy represents an
established and accepted ‘‘theranostic’’ approach. In
1942, Pecher demonstrated that 89Sr accumulates in bone
tumors in animals; and later, these findings were trans-
lated to humans and 89Sr was widely used in cancer
patients [2, 3]. More recently, a number of new thera-
nostic approaches have been introduced including
123I-/131I-labeled Metaiodobenzylguanidine (MIBG) for
diagnosis and treatment of neuroblastoma [4–6]. An
additional theranostic pair consisting of 123I- and 131I-
metomidate for diagnosis and treatment of adrenocortical
carcinomas (ACC) has been established at the University
Hospital of Wu¨rzburg. The diagnostic scan with 123I-
metomidate allows for the prediction whether an ACC
patient will benefit from 131I-metomidate radionuclide
therapy after determination of an individualized dose by
dosimetry [7, 8]. First, clinical data revealed tumor
control in half of the patients undergoing 131I-metomi-
date therapy [7, 9].
In this article, we focus on the recently introduced and
clinically translated ‘‘theranostic approach’’ of somato-
statin receptor (SSTR) targeting compounds for treatment
of patients with neuroendocrine tumors (NETs). We will
present an overview of its role for diagnosis, staging and
restaging, discussing its way to being established in
clinical routine, and giving an outlook about new
developments.
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Theranostic twins in NET
The term ‘‘theranostics twins’’ includes diagnostic molec-
ular imaging followed by a personalized treatment decision
based on the predictive value of the diagnostic scan.
Translated to NETs ‘‘theranostic twins’’ relate to the pair-
ing of 111In-/68Ga-labeled diagnostic imaging and
90Y-/177Lu-labeled treatment compounds targeting the
SSTR (Fig. 1).
The rationale of this theranostic approach bases on the
fact that well-differentiated NETs usually overexpress
SSTR on their tumor cell surface which may serve as
diagnostic and therapeutic targets [10]. Five different
membrane-bound receptors have been evaluated: SSTR1,
SSTR2, SSTR3, SSTR4 and SSTR5. Out of these potential
targets usually SSTR2 is addressed for diagnosis and
therapy. Using radiolabeled somatostatin analogs for
functional imaging the diagnosis of NETs can be confirmed
and the tumor burden (metastases) assessed. These nuclear
medicine imaging procedures provide essential information
about SSTR density, which is relevant for treatment deci-
sions, and selecting patients for treatment with peptide
receptor radionuclide therapy (PRRT) [11]. In general,
PRRT is recommended in inoperable, metastasized cases
expressing SSTR on tumor cell surface [12].
111In-labeled twins
111In-DTPA-octreotide, binding to SSTR2, was the first
and most widely used radiopharmaceutical for detecting
and staging NETs [13]. Planar images should be per-
formed and, if available, single photon emission com-
puted tomography (SPECT) after 4 and 24 h [14]. With
an overall sensitivity of 80 % 111In-DTPA-octreotide
scintigraphy (including SPECT) seems to be an effective
method to detect tumor burden [15]. However, reduced
detection rate has been reported in small and deep-seated
lesions, even when using hybrid SPECT/CT scanners
[16]. Historically verified, 111In can not only be used for
diagnosis and staging of NETs, but also for treatment:
treating 40 patients by using the Auger electron emitting
radionuclide 111In, partial remission (PR) was reported in
one patient, minor remission in six patients and stable
disease (SD) in 14 patients [17]. In another study, only
two of 27 patients (8 %) showed imaging-based mor-
phological PR [18]. Due to the short particle range and
the resulting limited tissue penetration, tumor regression
only rarely occurred [19].
Thus, in the previous decade, the use of 111In was






Fig. 1 69-year-old male suffering from Ileum NET (primary tumor)
with paraaortal thoracic lymph node metastases. Left pretherapeutic
68Ga-DOTATOC PET/CT (anterior view, trans-axial view) showing
primary tumor (ileum) and paraaortal mediastinal lymph node
metastases. Right posttherapeutic fused SPECT/CT after administer-
ing 7.4 GBq 177Lu-DOTATATE showing prominent uptake in the
primary tumor and paraaortal thoracic lymph node metastases
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68Ga and 90Y/177-Lu labeled twins
Recently, PET tracers have replaced 111In-DTPA-octreo-
tide for diagnostic imaging of NETs. Three 68Ga labeled
somatostatin analogs are currently routinely used in clinical
practice: 68Ga-DOTA-D-Phe-Tyr3-octreotide (DOTA-
TOC), 68Ga-DOTA-1-Nal(3)-octreotide (DOTANOC) and
68Ga-DOTA-D-Phe-Tyr3-octreotate (DOTATATE). All
these compounds bind with a high affinity to SSTR2 on the
tumor cell surface [16]. Compared with 111In-DTPA-
octreotide, 68Ga-DOTATATE PET/CT was found to be the
superior functional imaging modality especially in small
lesions with a low density of SSTRs because of its higher
resolution [20]. Initial results were confirmed by Haug
et al. in a larger patient cohort. Offering better imaging
properties, 68Ga-SSTR PET/CT was able to depict NETs
with an accuracy of 87 % [21] (Fig. 2). In 2010, conven-
tional imaging’s such as CT or endoscopic ultrasound were
compared to PET/CT in 90 patients. SSTR PET/CT led to a
modification of staging in 29 % and management of ther-
apy in 76 % of patients [22]. Additionally, PET is more
patient friendly since it can be done as a single imaging
session performed within 30–60 min after injection [16] as
opposed to multiple day imaging required for 111In- DTPA-
octreotide scintigraphy.
Currently, the most commonly used isotopes for treat-
ment intended radiolabeling of somatostatin analogs are the
ß-emitting isotopes 90Y with DOTATOC or ß- and
y-emitting 177Lu with DOTATATE. Otte et al. [23]
reported treatment in a palliative setting of 29 patients with
advanced SSTR-positive tumors by administering at least
3.7 GBq of 90Y-DOTATOC in 127 single treatment cycles.
Only three patients suffered from progressive disease.
Waldherr et al. [24] injected 7.4 GBq 90Y-DOTATOC (4
treatment cycles, time interval of 6 weeks) resulting in 5 %
complete responses (CR) and 18 % PR. The most common
reported side effect was renal impairment with a decline in
creatinine clearance of 7.3 % per year [25].
However, 177Lu-DOTATATE seems to be better toler-
ated than 90Y [25]. Thus, it is also routinely used as the
‘‘theranostic twin’’ to 68Ga. 310 NET patients treated with
27.8–29.6 GBq (4 treatment cycles, time interval of
6–10 weeks) showed a survival benefit of 40–72 months
from diagnosis in comparison to historical controls [26].
Quality of life improved significantly after 177Lu-DOTA-
TATE [27] and even in patients undergoing repeat salvage
Fig. 2 56-year-old male
suffering from unresectable
pancreatic NET (primary tumor)




(anterior view, trans-axial view)




PET/CT (anterior view, trans-
axial view) after administering
22.3 GBq 177Lu-DOTATOC
over the course of 3 treatment
cycles showing reduced uptake
in the metabolically regressive
liver and retroperitoneal lymph
node metastases (staging
10 weeks after last treatment
cycle)
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PRRT a median PFS of 13 months was reported [28]. At
least two treatment cycles should be performed because
PFS seems to be determined by the injected dose [29]. The
most important delayed side effects significant renal
impairment and myelosuppression occur in approximately
1 % of patients [30, 31]. Amino acid (AA) solutions are
recommended directly prior and during PRRT to reduce
renal absorbed dose and subsequent damage to the renal
parenchyma. Treating physicians should be aware of
potentially life-threatening acute hyperkalemia which can
occur as an acute side effect, of administering AA [14, 32].
Because of deeper tissue penetration the high energy
90Y beta emitter is recommended for larger lesions,
whereas the lower energy 177Lu should be administered for
smaller lesions. A combination of 90Y-/177Lu-DOTATATE
demonstrates better therapy response in comparison to
single-injection of 90Y-DOTATATE by providing a sig-
nificantly longer median OS [33].
The term ‘‘theranostics’’ emphasizes the inseparability of
diagnosis and therapy. However, individual treatment plan-
ning determining prognosis should be part of this concept.
68Ga-DOTATATE PET/CT can also predict progression-
free-survival (PFS) in patients undergoing PRRT: Evaluat-
ing the early prediction of clinical outcome 3 months after
the initial treatment cycle, the tumor-to-spleen SUV ratio
was able to independently predict the time-to-progression in
patients undergoing SSTR PET/CT [34].
In summary, the diagnosis and therapy monitoring of
NETs can be assessed by using functional imaging with
different somatostatin analogs. 111In-labeled twins were
used in the last decade showing a good overall sensitivity
and treatment effects. However, in small and deep-seated
lesions, 68Ga-labeled radiopharmaceuticals for PET are
superior, even superior to stand alone contrast-enhanced
multislice CT [35]. For its twin, 177Lu or 90Y DOTATATE/
DOTATOC, good results for overall survival, improvement
of quality of life but also less side effects were demon-
strated [26, 27].
Theranostic approach in clinical routine
Nowadays, the most commonly used ‘‘theranostic twins’’
for treatment of NETs are 68Ga and 90Y-/177Lu-DOTA-
TATE/DOTATOC showing higher response rates and
improvement of life quality [14].
Labeling of the twins
Preparation of radiopharmaceuticals should be performed
according to the current regulations on radiation protection
and guidelines on Good Radiopharmacy Practice ensuring
strict hygiene requirements [36].
68Ga PET is usually used for pre-therapeutic proof of
target expression, for staging and follow-up of patients.
The half-life of the 68Ga isotope is favorable with 68 min.
The use of a 68Ge/68Ga-generator ensures a continuous
cyclotron-independent supply with 68Ga [37]. The only
stable chemical form of Ga at physiological conditions is
Ga3? which still needs a bifunctional chelating agent
(BCA) to bind to a target vector such as peptides or pro-
teins [38]. Since the labeling process can be performed just
prior to the PET/CT examination it is possible to inject an
optimal amount of radioactivity.
177Lu is produced by a nuclear reactor in two different
ways: via ‘‘direct pathway’’ (irradiation of 176Lu) or via
‘‘indirect pathway’’ (irradiation of 176Yb producing 177Yb
decaying to 177Lu). A specific activity of 37–74 MBq 177Lu
per microgram is generally recommended [14]. The
method of synthesis is widely described in literature [39–
41].
Therapeutic procedure
Like any other nuclear medicine therapy, PRRT has to be
performed according to the local legal and ethical
requirements and a recommendation of a multidisciplinary
tumor board is desirable. The ward of the nuclear medicine
department must provide trained staff including physicians,
radiochemists and medical physicist experts. General
radiation safety arrangements are mandatory. However,
official regulations with special focus on radionuclides
used for PRRT do not exist; in summary, these require-
ments differentiate from one country to another [14].
Toward intercontinental patient care
In Japan and other non-European countries, PRRT using
effective SSTR-targeting compounds like 177Lu-DOTA-
TOC are currently not available. To implement the entire
‘‘theranostic’’ concept, the use of the ‘‘theranostic twins’’
but also individual tailored treatment planning prior to
PRRT is indispensable. To overcome this shortcoming, the
Wu¨rzburg department of nuclear medicine among others
provides special medical services for patients which do not
have access to PRRT in their home countries including
patient preparation at their home institution (e.g. renal
scintigraphy, 111In-DTPA-octreotide scintigraphy). Addi-
tionally, management of transfer to Germany is provided.
If required also in-house renal scintigraphy, measurement
of blood values (with special focus on renal/hematological
parameters) but also the more sensitive 68Ga-DOTATOC
PET/CT scan proving receptor expression on tumor cell
surface can be provided. To avoid environmental radiation
exposure after PRRT as well as to guarantee a better post-
therapy monitoring, the patients are constrained to stay
4 Ann Nucl Med (2015) 29:1–7
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hospitalized for a total of 3–5 days. After being discharged,
patients are encouraged to avoid contact to small children
and pregnant persons for the next 5–7 days; special
paperwork to allow for a return flight will be provided.
Dose estimation as part of ‘‘theranostic’’ concept
to minimize toxicity
The term ‘‘theranostic twins’’ does not only refer to the
use of peptides labeled with diagnostic or therapeutic
radionuclides, but also emphasizes the personalized
patient preparation prior to and after PRRT. The kidneys
are the dose-limiting organ in PRRT and therefore kid-
ney function has to be assessed prior to therapy by
laboratory tests, 24 h urine collection and/or renal scin-
tigraphy [14]. Van Binnebeek et al. reported in a case
presentation as well as in a prospective phase II trial on
the role of individualized dosimetry-based activity
reduction of 90Y-DOTATOC to prevent severe and rapid
kidney function deterioration by maximizing the deliv-
ered tumor dose and minimizing the biological effective
dose (BED) to potential risk organs (kidney, bone mar-
row). The authors used 111In-pentetreotide for dose
estimation and reported a maximal tolerable kidney dose
of 37 Gy BED as the threshold to avoid severe loss of
kidney function in 90Y-DOTATOC [42, 43].
Helisch et al. [44] demonstrated that both 86Y-
DOTATOC (chemically identical to 90Y) and 111In-pen-
tetreotide are feasible to pre-therapeutically calculate the
cumulative organ and tumor doses identifying patients
with high radiation burden to the kidneys. Concerning
post-therapeutic dosimetric approaches, the following data
has to be collected up to 3 days after PRRT: urine, blood,
whole-body-scans, planar images but also SPECT alone/
fused-SPECT/CT [14]. Software tools like OLINDA/
EXM using this equation provide internal dose informa-
tion and especially dose calculations [45]. However, a
general recommendation for performing pre-/post-thera-
peutic dosimetry is not given. Due to its y-emission, post-
therapeutic scintigraphy of 177Lu-DOTATATE allows
staging/imaging and dosimetry by using the same radio-
labeled tracer. Thus, during the first treatment cylce of
177Lu-DOTATATE, a post-therapeutic dosimetry might
be useful [14, 46].
Outlook
In general, PRRT is recommended for inoperable, metas-
tasized NETs expressing SSTR2 on the tumor cell surface
[12].
Radiosensitizing, SST receptor expression increase
and neoadjuvant treatment strategies
The synergism of radiolabeled compounds with chemo-
therapy may lead to higher efficacies. Claringbold et al. [47]
reported that the addition of the radiosensitizing chemo-
therapeutic drug capecitabine resulted in tumor control in
94 % of patients without severe toxicity. The same research
group administered 177Lu-octreotate in combination with
capecitabine and temzolomid in advanced low-grade NETs
demonstrating 2-year survival rate of 90 % [48].
Furthermore, receptor expression on tumour cells could
be increased by addressing different molecular targets prior
to PRRT. This might guarantee a higher saturation of SST
receptors expressed on the tumor cell surface which could
lead to higher BED. A Swedish research group reported a
higher uptake of 177Lu-DOTA-Tyr3-octreotate in external-
beam irradiated small cell lung cancer cells which might be
caused by an up-regulation of SSTR2 [49]. These findings
may constitute a promising treatment option in the future.
On a final note, the use of PRRT in a neoadjuvant setting
to downstage/downsize inoperable patients could be ben-
eficial but has not been studied sufficiently to date.
Locoregional procedures in case of discontinuing
PRRT
Radioembolization with 90Y microspheres has been
described as a safe and effective treatment option in un-
resectable cancers of the liver [50]. Due to their hyper-
vascularity liver-dominant NET metastases are well-suited
for locoregional therapeutic procedures such as radioemb-
olization (selective internal radiation therapy, SIRT) but
also transarterial chemoembolization (TACE) combining
the cytotoxic effect of intra-arterial chemotherapy with an
embolizing ischemic approach [51]. Injection of 90Yttrium-
microspheres into liver metastases as salvage therapy after
PRRT resulted in a median OS of 29 months [52]. TACE
and transarterial embolization (TAE) demonstrated the
same PFS of 36 months in patients suffering from
advanced NET. However, less side effects are described for
TAE [53].
‘‘High dose’’ approach in PRRT
Ongoing studies are trying to determine the role of
dosimetry for minimizing kidney and bone marrow damage
by potentially offering the possibility of increasing the
administered activities. Currently, up to a maximum of
7.4 GBq per treatment cycle is regarded as safe [54]. Using
the absorbed dose to ‘‘risk organs’’ as the limiting factor,
treatment with 177Lu-DOTATATE could be individualized
Ann Nucl Med (2015) 29:1–7 5
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to avoid under-/overtreatment, minimize side effects and to
be able to administer the maximum activity per treatment
cycle. Forrer et al. [55] reported high inter-patient vari-
ability of bone marrow absorbed doses. Thus, individual
dosimetry and a personalized ‘‘high dose’’ approach appear
feasible. Results of standard PRRT (by using 7.4 GBq
177Lu-DOTATOC) according to practical guidance [14]
could be compared to a tailored ‘‘high dose’’ treatment by
injecting the maximum tolerable dose per cycle. Pre-ther-
apeutic dosimetry assesses the individual kinetic behavior
in every patient which might be helpful in maximizing the
cumulative dose but also optimizing the BED.
Conclusion
In summary, PRRT is an effective and safe treatment
option for patients suffering from advanced NET. The
‘‘theranostic twins’’ 177Lu- and 68Ga-DOTATATE are
routinely used in clinical practice with well-established
response rates. Ongoing prospective multicenter trials such
as NETTER-1 will hopefully confirm these results in larger
patient populations awarding PRRT a higher clinical
acceptance [56]. The importance of dose estimation as part
of the ‘‘theranostic’’ concept and also pre-therapeutic up-
regulation of SSTR expression should be kept in mind as
potential innovations of PRRT [42, 43, 49].
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